Roy S. Herbst, MD, PhD

Articles

Dr. Herbst on the Approval of Adjuvant Osimertinib in EGFR+ NSCLC

January 6th 2021

Roy S. Herbst, MD, PhD, discusses the approval of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Dr. Herbst on Biomarkers for Immunotherapy Response in NSCLC

December 16th 2020

Roy S. Herbst, MD, PhD, discusses biomarkers for immunotherapy response that are currently under investigation in non–small cell lung cancer (NSCLC).

Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLC

June 2nd 2020

Roy S. Herbst, MD, PhD, discusses the benefit of adjuvant osimertinib demonstrated in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial.

Dr. Herbst on Combination of Nivolumab and Ipilimumab in Patients With NSCLC

January 22nd 2020

Roy S. Herbst, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced non–small-cell lung cancer (NSCLC).

Dr. Herbst on Immuno-Oncology Combinations in Lung Cancer

July 26th 2019

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses combinations with immunotherapy in lung cancer.

Dr. Herbst on Immune Resistance in Lung Cancer

November 12th 2018

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.

Dr. Herbst on Long Term Survival With Pembrolizumab in NSCLC

October 25th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses long-term survival of patients with non–small cell lung cancer (NSCLC) treated with pembrolizumab (Keytruda).

Dr. Herbst Discusses Challenges With Immunotherapy in NSCLC

August 27th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses challenges with immunotherapy in non–small cell lung cancer.

Dr. Herbst on Key Immunotherapy Findings in NSCLC

August 10th 2018

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses key immunotherapy findings in non–small cell lung cancer, presented at the 2018 ASCO Annual Meeting.

Dr. Herbst on TMB as a Biomarker in NSCLC

August 3rd 2018

Roy S. Herbst, MD, PhD, professor of medicine, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses tumor mutational burden (TMB) as a biomarker in non–small cell lung cancer (NSCLC).

Dr. Herbst on Intriguing Immunotherapy Combinations in NSCLC

July 28th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses immunotherapy combinations that have potential in non-small cell lung cancer (NSCLC).

Dr. Herbst on the Bevacizumab Biosimilar in Lung Cancer

July 11th 2018

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the bevacizumab (Avastin) biosimilar in lung cancer.

Dr. Herbst on a Smoking Cessation Trial for Lung Cancer

May 30th 2017

Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses a smoking cessation trial for patients with lung cancer.

Dr. Herbst on Combination Therapies for Lung Cancer

January 20th 2017

Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses combination therapies for patients with lung cancer.

Dr. Herbst on the Impact of Frontline Immunotherapy in Lung Cancer

January 7th 2017

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the impact that immunotherapy has had on the frontline treatment of patients with lung cancer.

Dr. Herbst on Advances of Immunotherapy in Lung Cancer

October 14th 2016

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, associate director for Translational Research, Disease Alligned Research Team Leader, Thoracic Oncology Program, Yale Cancer Center, discusses the current and future impact of immunotherapy in lung cancer.

Dr. Herbst on Next-Generation Agents in NSCLC

August 6th 2016

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, associate director for Translational Research, Disease Alligned Research Team Leader, Thoracic Oncology Program, Yale Cancer Center, discusses the next generation of agents coming down the pipeline in non–small cell lung cancer.

Dr. Herbst on Nivolumab for NSCLC

April 22nd 2015

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discuses the impact of the FDA's approval of nivolumab's for the treatment of squamous non-small cell lung cancer.

Dr. Herbst Discusses the State of Immunotherapy in Lung Cancer

November 18th 2014

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the state of immunotherapy in lung cancer.

Dr. Herbst on the Next Generation of Lung Cancer Trials

October 1st 2014

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.